ARTICLES BY CLIFF MINTZ

• 14-Year Quest For An Approved Orphan Disease Drug

  6/1/2012

  Stuart Peltz founded Post-Transcriptional Control Therapeutics (PTC) to identify and commercialize small molecule drugs that work at the post-transcriptional level to modify protein production in therapeutics. By Cliff Mintz, Ph.D., Contributing Editor

• Antibacterial Drug Discovery And Beyond

  7/11/2011

  To bolster its therapeutic MAb (monoclonal antibody) development pipeline, in 2006, AstraZeneca purchased United Kingdom-based Cambridge Antibody Technology, and shortly thereafter, in 2007, acquired MedImmune for $15.6B. By Cliff Mintz Ph.D., Life Science Leader magazine